PLGA-modified Syloid<sup>®</sup>-based microparticles for the ocular delivery of terconazole: in-vitro and in-vivo investigations

Zaghloul, Nada; Mahmoud, Azza A.; Elkasabgy, Nermeen A.; Hoffy, Nada M. El

doi:10.1080/10717544.2022.2092239

Cited by 9 publications

(4 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The validated HPLC analysis was performed using an isocratic mode, Agilent 1200 series HPLC instrument (Agilent Technologies Inc., Santa Clara, CA, USA) according to the United State Pharmacopoeia with some modifications [ 23 ]. The drug was eluted through ACE ® C18-1104 reverse phase column (150 × 4.6 mm, 5 µm, Advanced Chromatography Technologies Ltd., Scotland, UK) with a guard column.…”

Section: Methodsmentioning

confidence: 99%

Ketorolac-Loaded PLGA-/PLA-Based Microparticles Stabilized by Hyaluronic Acid: Effects of Formulation Composition and Emulsification Technique on Particle Characteristics and Drug Release Behaviors

et al. 2023

View full text Add to dashboard Cite

This study aimed to develop ketorolac microparticles stabilized by hyaluronic acid based on poly(lactide-co-glycolide) (PLGA), poly(lactide) (PLA), and their blend for further application in osteoarthritis. The polymer blend may provide tailored drug release and improved physicochemical characteristics. The microparticles were prepared by water-in-oil-in-water (w/o/w) double emulsion solvent evaporation using two emulsification techniques, probe sonication (PS) and high-speed stirring (HSS), to obtain the microparticles in different size ranges. The results revealed that the polymer composition and emulsification technique influenced the ketorolac microparticle characteristics. The PS technique provided significantly at least 20 times smaller average size (1.3–2.2 µm) and broader size distribution (1.5–8.5) than HSS (45.5–67.4 µm and 1.0–1.4, respectively). The encapsulation efficiency was influenced by the polymer composition and the emulsification technique, especially in the PLA microparticles. The DSC and XRD results suggested that the drug was compatible with and molecularly dissolved in the polymer matrix. Furthermore, most of the drug molecules existed in an amorphous form, and some in any crystalline form. All of the microparticles had biphasic drug release composed of the burst release within the first 2 h and the sustained release over 35 days. The obtained microparticles showed promise for further use in the treatment of osteoarthritis.

show abstract

Section: Methodsmentioning

confidence: 99%

Ketorolac-Loaded PLGA-/PLA-Based Microparticles Stabilized by Hyaluronic Acid: Effects of Formulation Composition and Emulsification Technique on Particle Characteristics and Drug Release Behaviors

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Other nanotechnology-based drug delivery systems for ocular application include dendrimers [94,95], nanomicelles [96,97], microparticles [98,99], and inorganic which comprise gold nanoparticles and magnetic nanoparticles [79,100]. Nanomicelles are, indeed, the carriers most frequently used to formulate drugs in clear aqueous media.…”

Section: Other Biodegradable Nanocarriersmentioning

confidence: 99%

Precision Medicines for Retinal Lipid Metabolism-Related Pathologies

Ana

Gliszczyńska

García

et al. 2023

JPM

View full text Add to dashboard Cite

Oxidation of lipids and lipoproteins contributes to inflammation processes that promote the development of eye diseases. This is a consequence of metabolism dysregulation; for instance, that of the dysfunctional peroxisomal lipid metabolism. Dysfunction of lipid peroxidation is a critical factor in oxidative stress that causes ROS-induced cell damage. Targeting the lipid metabolism to treat ocular diseases is an interesting and effective approach that is now being considered. Indeed, among ocular structures, retina is a fundamental tissue that shows high metabolism. Lipids and glucose are fuel substrates for photoreceptor mitochondria; therefore, retina is rich in lipids, especially phospholipids and cholesterol. The imbalance in cholesterol homeostasis and lipid accumulation in the human Bruch’s membrane are processes related to ocular diseases, such as AMD. In fact, preclinical tests are being performed in mice models with AMD, making this area a promising field. Nanotechnology, on the other hand, offers the opportunity to develop site-specific drug delivery systems to ocular tissues for the treatment of eye diseases. Specially, biodegradable nanoparticles constitute an interesting approach to treating metabolic eye-related pathologies. Among several drug delivery systems, lipid nanoparticles show attractive properties, e.g., no toxicological risk, easy scale-up and increased bioavailability of the loaded active compounds. This review analyses the mechanisms involved in ocular dyslipidemia, as well as their ocular manifestations. Moreover, active compounds as well as drug delivery systems which aim to target retinal lipid metabolism-related diseases are thoroughly discussed.

show abstract

“…Microscopic images were taken with a scanning electron microscope (Philips, CM 200, acceleration voltage 200 kV, resolution 0.23 nm). Nanoparticles were coated with chromium for better resolution [19].…”

Section: Scanning Electron Microscopy (Sem)mentioning

confidence: 99%

Formulation and Evaluation of Aspirin-Loaded Plga Nanoparticles for Ophthalmic Use

Pethe

SHANBHAG

SHERJE³

et al. 2023

Int J App Pharm

View full text Add to dashboard Cite

Objective: The objective of this work was to increase the bioavailability of Aspirin to the retina by increasing its bioavailability to blood. This was achieved by forming aspirin-loaded PLGA nanoparticles Methods: Aspirin-loaded PLGA nanoparticles were prepared by a solvent evaporation process. The PLGA was dissolved in the proper solvent and added dropwise to the Aspirin-albumin solution revolving at 3000 rpm. Glutaraldehyde was used as a cross-linker at 20% concentration. The nanoparticles were obtained after passing the solution through HPH and subsequent centrifugation. Results: The prepared nanoparticles were found to be spherical with the smooth surface as seen in SEM. and with a size of 160.9 nm. Aspirin-loaded PLGA nanoparticles showed in vitro drug release of 71.4 % and ex-vivo permeation of 66.2 %. The formulation was found to be stable for six months. Conclusion: The developed aspirin-loaded polymeric nanoparticles could be effective for the controlled delivery of aspirin in the early prevention of diabetic retinopathy.

show abstract

PLGA-modified Syloid^®-based microparticles for the ocular delivery of terconazole: in-vitro and in-vivo investigations

Cited by 9 publications

References 49 publications

Ketorolac-Loaded PLGA-/PLA-Based Microparticles Stabilized by Hyaluronic Acid: Effects of Formulation Composition and Emulsification Technique on Particle Characteristics and Drug Release Behaviors

Ketorolac-Loaded PLGA-/PLA-Based Microparticles Stabilized by Hyaluronic Acid: Effects of Formulation Composition and Emulsification Technique on Particle Characteristics and Drug Release Behaviors

Precision Medicines for Retinal Lipid Metabolism-Related Pathologies

Formulation and Evaluation of Aspirin-Loaded Plga Nanoparticles for Ophthalmic Use

Contact Info

Product

Resources

About

PLGA-modified Syloid®-based microparticles for the ocular delivery of terconazole: in-vitro and in-vivo investigations

Cited by 9 publications

References 49 publications

Ketorolac-Loaded PLGA-/PLA-Based Microparticles Stabilized by Hyaluronic Acid: Effects of Formulation Composition and Emulsification Technique on Particle Characteristics and Drug Release Behaviors

Ketorolac-Loaded PLGA-/PLA-Based Microparticles Stabilized by Hyaluronic Acid: Effects of Formulation Composition and Emulsification Technique on Particle Characteristics and Drug Release Behaviors

Precision Medicines for Retinal Lipid Metabolism-Related Pathologies

Formulation and Evaluation of Aspirin-Loaded Plga Nanoparticles for Ophthalmic Use

Contact Info

Product

Resources

About

PLGA-modified Syloid^®-based microparticles for the ocular delivery of terconazole: in-vitro and in-vivo investigations